Nivestym is not the first biosimilar of Neupogen, which helps chemotherapy patients recover, but it reflects the Food and Drug Administration’s emphasis on bringing more biosimilars to market.
Pfizer’s biosimilar for chemo patients OK’d to vie against Amgen’s Neupogen
